BACKGROUND The prognosis of ST-segment Elevation Myocardial Infarction (STEMI) remains hugely different. Risk stratification is therefore very important for individual patient in terms of prognostic estimation and medical regiment planning. However, the ways for stratification are far from uniform. Evaluations are made based on different considerations but largely dependent on doctors' own experiences. We presumed that a classification based on different pathophysiological stages would be an objective way to stratify patients.
METHODS 140 first-STEMI patients were classified as: grade 0, no detectable myocardial necrosis; grade 1, with myocardial necrosis; grade 2, myocardial necrosis with reduced left ventricular ejection fractions (LVEF); grade 3, reduced LVEF accompanied with cardiac remodeling; grade 4, apparent mitral regurgitation additional to the grade-3 criteria. To guarantee the equal comparison, myocardial necrosis, infarction size and cardiac remodeling was determined by cardiac magnetic resonance while mitral regurgitation and cardiac improvements were assessed by echocardiography. RESULTS 1.4%, 42.1%, 27.2%, 25% and 4.3% patients were classified as grade 0 to grade 4, respectively. According rate of 90-day MACEs (any death, resuscitated cardiac arrest, acute heart failure and stroke) was 0%,5.1%, 7.9%, 47.1% and 71.4% (p<0.001). Grade-2 patients had more LVEF improvements than grade-3/4 patients after 90 days (44.7% vs 18.4%, p<0.001). Both the classification and the infarction size were independent predictors for 90-day MACEs. However, without the necessity to quantify infarction extent directly, the classification is a good reflection of infarction size (0AE0%, 16.78AE9.49%, 24.53AE10.18%, 36.59AE13.05% and 40.33AE15.82% by grade 0 to 4, P<0.001) and has a comparable prognostic value as the infarction size(0.822 vs. 0.815, p¼0.855 by C-statistics). METHODS A prospective cohort analysis was performed on all STEMI patients (symptom onset <24 hours from hospital admission) who underwent primary PCI with BVS implantation in different Italian Hospitals. The primary endpoint of the study was procedural success, defined as BVS implantation at the "culprit" lesion site with less than 30% final stenosis and TIMI 3 flow without in-hospital MACE (cardiac death, myocardial infarction [MI] or need for emergent target lesion revascularization [TLR] ). Furthermore, we evaluated the occurrence of cardiac death, MI, TLR and BVS thrombosis up to 9-month followup.
CONCLUSION
RESULTS Between December 2012 and February 2014, 1,232 STEMI patients underwent primary PCI. Of these, 74 (6.0%) received a BVS, 18 (24.3%) of them were multiple and overlapping. Procedural success was obtained in 72 (97.3%) cases without differences between the groups (overlapping BVS100% vs. single BVS 96.4%, p¼0.5). One patient experienced a re-infarction due to sub-acute BVS thrombosis while the other patient had a final TIMI flow 2. At 9-month follow-up, 2 non-fatal MI (2.7%), 3 TLR (4.1%), and 1 sub-acute BVS thrombosis were reported in 3 patients (1 [5.6%] overlapping BVS and 2 [3.6%] in the single BVS group, p¼0.5). All the events were successfully managed with re-PCI.
CONCLUSION Single or multiple overlapping BVS implantation in STEMI patients can be successfully performed with a high procedural success rate and encouraging 9-month outcomes. Larger randomized trials and longer follow-up are needed to assess the potential clinical benefit of BVS versus new-generation DES in this setting.
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Complete Versus Target-Vessel Revascularization in NSTEMI Patients BACKGROUND Acute myocardial infarction without ST segment elevation (NSTEMI) is the most common form of presentation of acute myocardial necrosis. Optimal therapeutic strategy in NSTEMI patients is a subject of debate -it has been shown recently that disturbed myocardial perfusion in the non-target coronary arteries is associated with worse prognosis and potential benefits of expanding the primary intervention to full instead of target-vessel revascularization are being discussed. The aim of this study is to compare the incidence of major adverse cardiac events (MACE) between NSTEMI patients with complete versus target-vessel revascularization.
METHODS We analyzed retrospectively 114 patients, mean age 67 AE 12 years, 69% male, hospitalized with NSTEMI between June and December 2012 and followed-up 12 months. Inclusion criteria were angiographic data for significant atherosclerotic involvement of more than one coronary artery and proceeding to percutaneous coronary intervention (PCI). 71 patients (62%) underwent target-vessel revascularization, the rest 43 (38%) -complete revascularization.
RESULTS Demographic and clinical characteristics did not differ significantly between groups except for smoking (more prevalent in target-vessel revascularization group). Procedure success was 91%in target-vessel revascularization group and 88% in patients with complete revascularization. Rate of early in-hospital complications was not significantly different between the groups: mortality -2 (2.7%) versus 1 (2.3%), periprocedural myocardial infarction -1(1.7%) versus 1(2.3%), in target-vessel and full revascularization groups, respectively.
During one-year follow-up combined incidence of MACE (mortality, myocardial infarction, revascularization) was significantly reduced after full revascularization (4 patients, 9.3%) compared to targetvessel intervention (12 patients, 9%), p <0.01. the difference in MACE was driven mainly from the significant reduction in the rate of repeat revascularization and mortality.
CONCLUSION NSTEMI patients have improved prognosis with complete versus target vessel revascularization during one-year followup, without increase in the rate of in-hospital complications. We assessed the hypothesis that a genetic risk score based on identified high-risk single nucleotide polymorphisms (SNPs) would be associated with bleedings in clopidogrel-treated Chinese STEMI patients after percutaneous coronary intervention (PCI). A total of 510 consecutive patients with STEMI who received an uneventful PCI and were exposed to clopidogrel treatment for 12 months, were enrolled in the single-center registry. There were 7 high-risk SNPs selected from ABCB1 (rs1045642, rs2235047), CYP2C19 (*17), PON1 (rs662, rs854560) and P2Y12 (rs6785930, rs6809699) genes, which were detected by the ligase detection reaction. The primary clinical safety endpoint was the incidence of major bleeding events. Major bleeding was quantified according to bleeding academic research consortium definition (BARC) criteria, including type 3 and 5 in the analysis. The follow-up period was 12months.
RESULTS Overall, 46 BARC!3 bleeding events (9.0%) occurred, which included 11 (2.2%) cases of BARC 3b bleedings and 35 (6.8%) cases of BARC 3a bleedings. After adjustment for traditional clinical risk factors, multivariate logistic regression analysis identified SNPs significantly associated with bleedings were ABCB1 (rs1045642, rs2235047) and P2Y12 (rs6785930, rs6809699). A genetic risk score was constructed by summing the number of risk alleles. As a continuous variable, the risk score resulted in an OR of 1.326 per unit increase in score (95%CI¼1.098-1.601, p¼0.003). The addition of this genetic risk score significantly increased AUC from 79.3% to 82.4% (p¼0.03), and significantly improved the predictive ability on bleeding risk by 20% using the NRI approach (p¼0.01).
CONCLUSION This genetic score was significantly associated with bleedings after PCI in our study population. (sCD40L) is associated with disease progression and severity in acute coronary syndrome (ACS), while it may provide a mechanistic link between inflammation and myocardial reperfusion as well as cardiac function. However, it is still controversial whether sequential therapy of higher doses of atorvastatin could provide more benefits in regulating sCD40L, coronary blood perfusion and ventricular function compared with a conventional dose in STEMI patients undergoing primary PCI.
METHODS After screening, 136 STEMI patients met the inclusion criteria and were included for analysis. All of them were divided into three groups by using an electronic spreadsheet indicating the group assignment by random numbers: Group A (n¼48) (received 80mg of Atorvastatin before primary PCI, post-PCI follow-up Atorvastatin 40mg for 1 month, and Atorvastatin 20mg for 5 months); Group B (n¼43) (received no pre-PCI loading dose of atorvastatin but did receive Atorvastatin 40mg for 1 month and then Atorvastatin 20mg for 5 months); Group C (n¼45) (received only post-PCI Atorvastatin for 6months). TIMI flow grade and Corrected TIMI Frame Count (CTFC) after PCI would be recorded and compared among three groups. In addition, the serum sCD40L and endothelial nitric oxide synthase (eNOS) would be measured at admission and 1-day, 7-day, 1-month, 6-month after PCI. Improvement of cardiac function would also be evaluated during the follow-up.
RESULTS Patients among the three groups were well matched in demographic and clinical characteristics (P>0.05). Patients in Group A exhibited much better myocardial reperfusion indicated by CTFC compared with Group B or Group C (no differences were observed in TIMI flow Grade 3 among three groups after PCI (P>0.05)). The levels of sCD40L in Group A were significantly lower than those in Group B or Group C on 1-day and 7-day (P<0.05), but not in later sampling points (P>0.05). Patients in Group A also gained higher levels of eNOS and showed improvement in heart performance, with significant increases in their left ventricular ejection fraction (LVEF) (P<0.05). Patients in Group B had relatively higher levels of eNOS as well as significant improvement in LVEF compared with Group C (P<0.05), although no statistical differences were observed in sCD40L comparison (P>0.05). No severe adverse reactions were observed during study period. BACKGROUND Recent studies of elderly patients demonstrate high mortality from acute myocardial infarction (AMI) and increased risk with advancing age. Although many oldest old AMI patients (! 85 years) have been treated by primary percutaneous coronary intervention (pPCI) in the aging society, the prognostic importance of early pPCI for these patients is unknown.
CONCLUSION
METHODS We evaluated consecutive 564 AMI patients (mean age 68.5 +/-12.9, male 77%) from Mie ACS Registry in Japan from January to December 2013. The pPCI was performed 86% patients. Patients were divided into two groups according to the age; oldest old patients (! 85 years old: n¼62) and non-oldest old patients (< 85 years old: n¼502). Primary end point was defined as 30 days in-hospital mortality.
RESULTS Percentage of chest pain at presentation of oldest old patients was tend to be lower than non-oldest patients (77 vs. 85%, p¼0.13). However, there was no difference for prevalence of pPCI between two groups, 30 days in-hospital mortality of oldest patients was significant higher than non-oldest patients (19.4 vs. 7%, p<0.01). Even in the patients with pPCI, oldest patients showed poor 30 days in-hospital mortality compared to the non-oldest patients (11.5 vs. 5.1%, p¼0.06). Only when analyzed patients with early pPCI (less than 12 hours after onset), oldest patients showed similar favorable prognosis to the non-oldest patients (Figure1A). However, oldest patients with delayed pPCI(more than 12 hours) showed poor prognosis compared to the non-oldest patients ( Figure 1B) . In
